Omadevi Somai
FDA investigator
Appears on 2 documents from 2019 to 2024, mostly at sites in New York. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80(b)).
- 2
- Documents on file
- 2.5
- Observations per 483
- 2019
- First seen
- 2024
- Most recent
What they cite most
From 5 observations- 21 CFR 314.80(b)Postmarketing reporting of adverse drug experiences4
- 21 CFR 314.81(b)(2)Other postmarketing reports1
Activity by year
2019: 1, 2024: 1
Where
New York 2
Often inspects with
Is Omadevi Somai coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2024-11-12 | 483 Amici Pharma IncNov 12, 2024 · Melville, New York | Melville, New York | 1 | |
| 2019-04-11 | 483 Jerome Stevens Pharmaceuticals, Inc.Apr 11, 2019 · Bohemia, New York | Bohemia, New York | 4 |
About this profile
What does Omadevi Somai inspect?
Omadevi Somai appears on 2 documents on file covering 2 sites, mostly in New York.
What do they cite most often?
21 CFR 314.80(b) (postmarketing reporting of adverse drug experiences), followed by 21 CFR 314.81(b)(2).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Omadevi Somai is dated Nov 12, 2024.